Flexion Therapeutics Inc (NASDAQ:FLXN) has earned a consensus rating of “Buy” from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.50.
Several research analysts recently commented on the company. Northland Securities assumed coverage on Flexion Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright initiated coverage on Flexion Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $25.00 price target for the company. Needham & Company LLC cut their price objective on Flexion Therapeutics from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, May 8th. ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Finally, Guggenheim initiated coverage on Flexion Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $20.00 price objective for the company.
In other news, CEO Michael D. Clayman purchased 10,256 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average cost of $9.75 per share, with a total value of $99,996.00. Following the acquisition, the chief executive officer now owns 64,957 shares in the company, valued at approximately $633,330.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 17.03% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in Flexion Therapeutics during the 1st quarter worth approximately $101,000. Squarepoint Ops LLC increased its stake in Flexion Therapeutics by 5.1% during the 1st quarter. Squarepoint Ops LLC now owns 41,043 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 1,987 shares during the period. Paloma Partners Management Co bought a new position in Flexion Therapeutics during the 1st quarter worth $92,000. Invesco Ltd. increased its stake in Flexion Therapeutics by 31.3% during the 1st quarter. Invesco Ltd. now owns 97,032 shares of the specialty pharmaceutical company’s stock worth $764,000 after acquiring an additional 23,129 shares during the period. Finally, Schroder Investment Management Group increased its stake in Flexion Therapeutics by 3.7% during the 1st quarter. Schroder Investment Management Group now owns 632,823 shares of the specialty pharmaceutical company’s stock worth $4,904,000 after acquiring an additional 22,633 shares during the period. 83.08% of the stock is owned by institutional investors and hedge funds.
NASDAQ FLXN traded up $0.29 during trading hours on Tuesday, hitting $12.98. 450,379 shares of the company traded hands, compared to its average volume of 914,677. The business’s 50-day moving average is $11.18 and its 200-day moving average is $13.54. Flexion Therapeutics has a twelve month low of $5.01 and a twelve month high of $22.98. The company has a debt-to-equity ratio of 27.76, a quick ratio of 4.52 and a current ratio of 5.08. The stock has a market capitalization of $484.70 million, a price-to-earnings ratio of -3.45 and a beta of 2.06.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.05. Flexion Therapeutics had a negative return on equity of 592.50% and a negative net margin of 175.76%. The firm had revenue of $20.13 million during the quarter, compared to analysts’ expectations of $18.45 million. Analysts predict that Flexion Therapeutics will post -2.83 EPS for the current year.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
See Also: What is a stock portfolio tracker?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.